Key result
Cardiac resynchronization therapy with a defibrillator (CRT-D) was associated with improved long-term survival compared to CRT pacing alone in mild heart failure.
Why the study?
Does CRT-D improve long-term survival compared to CRT-P in patients with mildly symptomatic heart failure?
RCT (n=419)
randomized
Yes
Does CRT-D improve long-term survival compared to CRT-P in patients with mildly symptomatic heart failure?
In patients with mildly symptomatic heart failure, receiving a CRT-D device rather than a CRT-P device is associated with significantly improved long-term survival.
Answers are grounded in this paper and cite their sources.
CRT-D may offer survival advantage over CRT-P in mild HF; leaves open need for randomized confirmation before practice change.
BACKGROUND: Cardiac resynchronization therapy (CRT) decreases mortality, improves functional status, and induces reverse left ventricular remodeling in selected populations with heart failure. These benefits have been noted with both CRT-pacemakers as well as those devices with defibrillator backup (CRT-D). However, there are little data comparing mortality between these 2 device types. METHODS AND RESULTS: REsynchronization reVErses Remodeling in Systolic left vEntricular dysfunction (REVERSE) was a multicenter, randomized trial of CRT among patients with mild heart failure. Long-term annual follow-up for 5 years was preplanned. The present analysis was confined to the 419 patients who were randomized to active CRT group. CRT-pacemakers or CRT-D devices were implanted based on national guidelines at the time of enrollment, with 74 patients receiving CRT pacemaker devices and the remaining 345 patients receiving CRT-D devices. After 12 months of CRT, changes in the clinical composite score, left ventricular end systolic volume index, 6-minute walk time, and quality of life indices were similar between CRT pacemaker and CRT-D patients. However, long-term follow-up showed lower morality in the CRT-D group. Specifically, multivariable analysis showed that CRT-D (hazard ratio, 0.35; P=0.003) was a strong independent predictor of survival. Female sex, longer unpaced QRS duration, and smaller baseline left ventricular end systolic volume index also were also associated with better survival. CONCLUSIONS: REVERSE demonstrated that the addition of implantable cardioverter-defibrillator therapy to CRT is associated with improved long-term survival compared with CRT pacing alone in mild heart failure. CLINICAL TRIAL REGISTRATION: URL: http://clinicaltrials.gov. Unique Identifier: NCT00271154.
No takes yet. Share an insight, caveat, or question.
Gold et al. (2013) conducted an RCT in mild heart failure (n=419). CRT-D (cardiac resynchronization therapy with defibrillator) vs. CRT-pacemaker was evaluated on survival (HR 0.35, p=0.003). Cardiac resynchronization therapy with a defibrillator (CRT-D) was associated with improved long-term survival compared to CRT pacing alone in mild heart failure.
Synapse has enriched 10 related papers. Consider them for comparative context: